Lexpos News

Following the recent announcement of the CPCF 2026/27 funding settlement, we know many of you have questions about what it means in practice for your pharmacy and your patients. To help provide clarity, we have answered some Frequently Asked Questions we’re hearing from pharmacy owners. Q. What is the expected change in income for an average pharmacy? In [...]

The post CPCF Settlement 2026/27: Frequently Asked Questions appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) Drug alert number: EL(26)A/28 Date issued: 08 June 2026 Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery. DMRC [...]

The post MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) (Crescent Pharma Limited livery) appeared first on Community Pharmacy England.

Community Pharmacy England is pleased to announce the appointment of Rahul Sharda, an independent pharmacy owner from Stoke-on-Trent, as the new Regional Representative Committee Member for the East and North Midlands. Rahul joins the Community Pharmacy England Committee will serve in this role until 31st March 2027, in line with the current committee term. To [...]

The post New East and North Midlands Regional Representative Appointed appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the May 2026 concessionary prices for Indometacin 25mg capsules & Sumatriptan 50mg tablets. Product Pack size Price concession Indometacin 25mg capsules 28 £11.20 (previously £10.24) Sumatriptan 50mg tablets 28 £6.26 (previously £5.85) [...]

The post Improved prices for Indometacin 25mg capsules & Sumatriptan 50mg tablets for May 2026 appeared first on Community Pharmacy England.

Following the announcement of the 2026/27 negotiations, a Drug Tariff update has been published to base the New Medicine Service (NMS) monthly consultation cap on 0.9% rather than 1.0% of monthly prescriptions. This change is unlikely to impact the majority of pharmacy owners; however, pharmacy owners are encouraged to review the new caps, as shown [...]

The post NMS: Change to monthly cap from June 2026 appeared first on Community Pharmacy England.